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Objectives: The primary objective was to determine the prevalence of cochlear
(C-DF) and vestibular (V-DF) dysfunction in patients with CF at LHSC. Secondary
objectives included determining if there is an association between aminoglycoside
(AMG) exposure or other risk factors and ototoxicity in CF patients.
Methods: 73 patients with C-DF and V-DF are needed to detect a 0−10%
prevalence rate with 95% conﬁdence. Patients with a diagnosis of CF were eligible
for study enrollment. Study participants completed audiometric testing to detect
C-DF. V-DF was detected by completing ﬁve standard balance tests. Additional
risk factors for ototoxicity, including AMG exposure, were investigated.
Results: 49 patients (1−48 years of age) completed audiometric testing and 37
patients completed balance testing. Of these, 4 (8.9%) patients had C-DF and
20 (54.1%) patients had V-DF. There was no statistically signiﬁcant difference
in the rate of C-DF and V-DF in patients exposed to AMG as compared to
those not exposed (C-DF, P = 0.812; V-DF, P = 0.051). Family history of hearing
loss, prematurity, loud noise exposure, or ototoxic medication use did not produce
statistically signiﬁcant higher rates of C-DF and V-DF.
Conclusion: The prevalence of C-DF and V-DF amongst CF patients at LHSC
appears to be 8.9% (95%CI 3.5−20.7%) and 54.1% (95%CI 38.4−69.0%) respec-
tively. The high rate of V-DF may be the result of physiological immaturity or acute
illness, as opposed to a pathological process. AMG exposure does not appear to
be associated with an increase in C-DF and V-DF rates amongst study participants
and no other risk factors were identiﬁed which may predispose CF patients to
ototoxicity.
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Objectives: Aminoglycoside antibiotics, commonly used for the treatment of pul-
monary exacerbations in cystic ﬁbrosis, are potentially toxic to renal proximal tubule
epithelial cells. A novel urinary biomarker, Kidney Injury Molecule-1 (KIM-1), has
speciﬁcity for proximal tubule injury. The aim of this study was to assess KIM-1
as a biomarker of aminoglycoside-induced nephrotoxicity in children with cystic
ﬁbrosis.
Methods: Baseline urine samples were collected from 44 children aged 0−16 years
with cystic ﬁbrosis, and before, during and after exposure to tobramycin in 10
of these children. KIM-1 was measured using a Meso Scale Discovery analytical
platform, and standardised to urinary creatinine.
Results: Mean baseline KIM-1 was 0.57 ng/mg Cr (95% Conﬁdence Interval
(CI), 0.40–0.73 ng/mg Cr, n = 44). There was a signiﬁcant correlation between
baseline KIM-1 and the number of previous courses of aminoglycosides (R=0.70,
P< 0.002). During exposure to tobramycin mean peak KIM-1 was signiﬁcantly
elevated from baseline (mean peak KIM-1, 1.24 ng/mg Cr, 95%CI, 0.71–1.78 ng/mg
Cr, p = 0.02, n = 10). Mean fold change [(peak KIM-1 during tobramycin exposure)/
(pre-treatment baseline KIM-1)] was 3.03 (95%CI, 1.89–4.17).
Conclusion: In children with cystic ﬁbrosis we have demonstrated signiﬁcant acute
changes in urinary KIM-1 during exposure to tobramycin, and an association of
baseline KIM-1 with previous aminoglycoside exposure. KIM-1 may be a useful,
non-invasive, biomarker of acute and chronic proximal tubular injury associated
with exposure to aminoglycosides in children with cystic ﬁbrosis.
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Objectives: There is a need to measure antibiotic resistance of Pseudomonas
aeruginosa (PA) in cystic ﬁbrosis (CF), either qualitatively or quantitatively, to
inform patient management. The aim of this study was to develop a simple method
by which resistance can be quantiﬁed by calculating a relative resistance index
(RRI), and to assess correlation of RRIs with clinical variables.
Methods: In our model, RRIs were calculated based on resistance to aztreonam,
ceftazidime, ciproﬂoxacin, colistin, meropenem, tazocin, temicillin and tobramycin.
Eighty-ﬁve adults with CF and chronic PA colonisation were identiﬁed. For each,
all PA cultures between 2010–2011 were allocated a score of 0 for susceptible, 0.5
for intermediate resistance or 1 for resistant for each antibiotic listed above, and
the RRI calculated by dividing the sum of these by the number of antibiotics. The
mean RRIs for all cultures over 2010–2011 were correlated with clinical variables
(including age, FEV1, IV antibiotic days and BMI).
Results: RRIs for non-mucoid PA exhibited signiﬁcant positive correlation with
total number of IV days (r = 0.405; p< 0.001) and signiﬁcant negative correlation
with FEV1% predicted (r = −0.437 p< 0.001). RRIs were not signiﬁcantly correlated
with duration of colonisation, typing (clonal vs other strain) or BMI. Median RRIs
were signiﬁcantly higher for females than males (0.26 vs. 0.14; p = 0.03) for non-
mucoid PA only. Meropenem resistance displayed the strongest negative correlation
with FEV1 % predicted.
Conclusion: In summary, RRI is an easily calculated measure which appears to
have clinical signiﬁcance, and enables quantitative monitoring of resistance over
time.
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Objectives: Pseudomonas aeruginosa (Pa) is the most common pathogen of cystic
ﬁbrosis (CF). We focused on Pa metalloproteases (MP). The modulation of Pa
virulence factors such as MPs was suggested as mechanism for azithromycin (AZM)
beneﬁcial effects in CF patients. Our work aimed to develop a highly reproducible
and easy method to detect MP activity in Pa clinical strains and establish the
sensitivity of it to AZM.
Methods: Fluorochrome-labeled substrate (FITC-gelatin) coated microspheres al-
lowed to evaluate MP activity in conditioned media (CM) from Pa clinical strains
and in sputa of CF patients and the effect of AZM treatment on Pa strains able to
release MPs.
Results: MP activity was measured in CM from 136 isolates classiﬁed as sporadic
and 134 deﬁned as chronic. Activity was detected in 100 of 136 sporadic strains
(73%) while this was true only for 70 of 134 (52%) chronic strains (p< 0.0001,
Fisher’s exact test). AZM treatment induced decrease of MP activity in 76 of
91 (83%) sporadic strains while it had a similar effect only on 28 of 56 chronic
strains (50%) (p< 0.0001, Fisher’s exact test). We measured MP activity in the
cell-free sputa from CF patients Pa chronically colonized being untreated or treated
with AZM (n = 37). A strong decrease of ﬂuoresce was detected in both conditions
(76.4% reduction average based on MFI values, for n = 14 untreated patients, 74.9%
reduction for n = 23 AZM-treated patients).
Conclusion: This method is sensitive and reproducible and allows a simple data
interpretation. AZM treatment decrease MP activity in Pa. Bacterial MP released
by Pa might contribute, along with leukocyte-derived enzymes, to lung damage in
CF patients.
